TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements in Critical Clinical Oncologic Patients: a Phase 3 Randomized Controlled Clinical Trial (TRICCOP STUDY)
Brief Summary: Blood transfusion in critical ill patients has been associated to several complications and worse outcome. Particularly in oncologic patients, red blood cell transfusion has been investigated as a factor of worse outcome and cancer recurrence due impairment of cellular immunity. Although red blood cell transfusion has decreased in worldwide clinical practice, this issue still remains a matter of controversy in oncologic patients. There are no prospective studies comparing outcomes between restrictive or liberal blood transfusion strategy in oncologic critical patients. This study is a prospective and randomized study comparing clinical outcomes between two strategies of transfusion in oncologic critical patients - liberal or restrictive.


Options:
A: Arm Label: Restrictive Red blood cell Transfusion; Type: EXPERIMENTAL; Interventions: Other: Red blood cell Transfusion | Arm Label: Liberal Red blood Cell Transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell Transfusion | Intervention Type: OTHER; Name: Red blood cell Transfusion; Assigned to Arm(s): Liberal Red blood Cell Transfusion, Restrictive Red blood cell Transfusion
B: Arm Label: Liberal transfusion strategy; Type: EXPERIMENTAL; Interventions: Other: Red Blood Cell Transfusions | Arm Label: Restrictive transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red Blood Cell Transfusions | Intervention Type: OTHER; Name: Red Blood Cell Transfusions; Assigned to Arm(s): Liberal transfusion strategy, Restrictive transfusion strategy
C: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
D: Arm Label: "liberal" transfusion triggers; Type: EXPERIMENTAL; Interventions: Other: red blood cell transfusion | Arm Label: "restrictive" transfusion triggers; Type: ACTIVE_COMPARATOR; Interventions: Other: red blood cell transfusion | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "liberal" transfusion triggers | Intervention Type: OTHER; Name: red blood cell transfusion; Assigned to Arm(s): "restrictive" transfusion triggers

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Transfusion Requirements in Critical Clinical Oncologic Patients: a Phase 3 Randomized Controlled Clinical Trial (TRICCOP STUDY)
Brief Summary: Blood transfusion in critical ill patients has been associated to several complications and worse outcome. Particularly in oncologic patients, red blood cell transfusion has been investigated as a factor of worse outcome and cancer recurrence due impairment of cellular immunity. Although red blood cell transfusion has decreased in worldwide clinical practice, this issue still remains a matter of controversy in oncologic patients. There are no prospective studies comparing outcomes between restrictive or liberal blood transfusion strategy in oncologic critical patients. This study is a prospective and randomized study comparing clinical outcomes between two strategies of transfusion in oncologic critical patients - liberal or restrictive.


Options:
A: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
B: Arm Label: Restrictive Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Procedure: Transfusion | Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transfusion | Intervention Type: PROCEDURE; Name: Transfusion; Assigned to Arm(s): Liberal Transfusion Strategy, Restrictive Transfusion Strategy
C: Arm Label: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Type: ACTIVE_COMPARATOR; Interventions: Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Arm Label: Allowed drop in hemoglobin to 5.6-6.5 mmol/L; Type: EXPERIMENTAL; Interventions: Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 5.6-6.5 mmol/L
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell transfusion | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma
Brief Summary: The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.


Options:
A: Arm Label: single arm of Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm of Tremelimumab
B: Arm Label: single arm with Tremelimumab; Type: EXPERIMENTAL; Interventions: Drug: Tremelimumab | Intervention Type: DRUG; Name: Tremelimumab; Assigned to Arm(s): single arm with Tremelimumab
C: Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pemetrexed disodium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: neoadjuvant therapy; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Trial of Hemodialysis Patient Aldosterone antagoniSm With Eplerenone Trial
Brief Summary: Forty percent of patients that require dialysis for kidney failure die within three years mostly due to heart disease. Heart failure and high blood pressure are common problems in patients that require dialysis and are key causes of death due to heart disease. Eplerenone is a drug that is very effective at improving heart failure and reducing blood pressure in patients that do not require dialysis. There is currently no evidence to tell physicians whether eplerenone would have similar benefits in patients that require dialysis. This evidence can only be reliably generated by performing a large scale study. Before such a study is undertaken, the investigators must determine whether eplerenone will be well tolerated and safe in patients that require dialysis. The investigators will perform an initial small trial called the Pilot trial in Hemodialysis patients undergoing Aldosterone antagoniSm with Eplerenone (PHASE) to determine if eplerenone is a well tolerated, safe medication to use in a very large, global study that will show whether or not eplerenone reduces important outcomes for patients like death from heart causes.


Options:
A: Arm Label: Eplerenone; Type: EXPERIMENTAL; Interventions: Drug: eplerenone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eplerenone; Assigned to Arm(s): Eplerenone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Losartan; Type: EXPERIMENTAL; Interventions: Drug: Losartan | Arm Label: spirolactone; Type: EXPERIMENTAL; Interventions: Drug: spirolactone | Arm Label: losartan in combination with spirolactone; Type: EXPERIMENTAL; Interventions: Drug: Losartan, Drug: spirolactone | Arm Label: blank control; Type: SHAM_COMPARATOR; Interventions: Other: blank control | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): Losartan, losartan in combination with spirolactone | Intervention Type: DRUG; Name: spirolactone; Assigned to Arm(s): losartan in combination with spirolactone, spirolactone | Intervention Type: OTHER; Name: blank control; Assigned to Arm(s): blank control
C: Arm Label: spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): spironolactone
D: Arm Label: Spironolactone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Wellness for Young Men
Brief Summary: This study assesses the impact of a mindfulness-based stress reduction program compared with a health education program for urban middle-school male youth on outcomes of psychological symptoms, coping, stress, sleep, and behavior.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Adolescent only Penn Resiliency Program (Adolescent PRP) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Adolescent only Penn Resiliency Program (Adolescent PRP), Behavioral: Parent Penn Resiliency Program (Parent PRP) | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adolescent only Penn Resiliency Program (Adolescent PRP); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Parent Penn Resiliency Program (Parent PRP); Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive behavior therapy (CBT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive/expressive (S/E) therapy | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Bibliotherapy | Arm Label: 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive behavior therapy (CBT); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Supportive/expressive (S/E) therapy; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Bibliotherapy; Assigned to Arm(s): 3
C: Arm Label: Intrinsic Motivation; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CATCH-IT Internet Site | Arm Label: Extrinsic Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BA (brief advice) + CATCH-IT Internet site | Intervention Type: BEHAVIORAL; Name: MI + CATCH-IT Internet Site; Assigned to Arm(s): Intrinsic Motivation | Intervention Type: BEHAVIORAL; Name: BA (brief advice) + CATCH-IT Internet site; Assigned to Arm(s): Extrinsic Motivation
D: Arm Label: Mindfulness-based stress reduction; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-based stress reduction | Arm Label: Healthy Topics; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Mindfulness-based stress reduction | Intervention Type: BEHAVIORAL; Name: Mindfulness-based stress reduction; Assigned to Arm(s): Healthy Topics, Mindfulness-based stress reduction

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
Brief Summary: This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to \<130 mmHg (intensive control) versus \<145 mmHg (standard control) slows/halts the progression of deterioration of mobility and cognitive function linked to white-matter disease (also known as white-matter hyperintensity or WMH) in patients with normal or mildly impaired mobility and cognition in subjects with detectable cerebrovascular disease (\>0.5% WMH fraction of intracranial contents). The study patients will be enrolled and randomized to one of two levels of ambulatory blood pressure control (intensive to achieve a goal 24-hour systolic blood pressure of \< 130 mmHg or standard to achieve a goal 24-hour systolic blood pressure of \< 145 mmHg) for a total of 36 months.


Options:
A: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard
B: Arm Label: 'Less tight' control.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention is blood pressure management approach | Arm Label: 'Tight' control.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Intervention is blood pressure management approach. | Intervention Type: PROCEDURE; Name: Intervention is blood pressure management approach; Assigned to Arm(s): 'Less tight' control. | Intervention Type: PROCEDURE; Name: Intervention is blood pressure management approach.; Assigned to Arm(s): 'Tight' control.
C: Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination of Telmisartan and Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A
D: Arm Label: Standard SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Arm Label: Intensive SBP Reduction Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous nicardipine hydrochloride | Intervention Type: DRUG; Name: Intravenous nicardipine hydrochloride; Assigned to Arm(s): Intensive SBP Reduction Arm, Standard SBP Reduction Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
Brief Summary: This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to \<130 mmHg (intensive control) versus \<145 mmHg (standard control) slows/halts the progression of deterioration of mobility and cognitive function linked to white-matter disease (also known as white-matter hyperintensity or WMH) in patients with normal or mildly impaired mobility and cognition in subjects with detectable cerebrovascular disease (\>0.5% WMH fraction of intracranial contents). The study patients will be enrolled and randomized to one of two levels of ambulatory blood pressure control (intensive to achieve a goal 24-hour systolic blood pressure of \< 130 mmHg or standard to achieve a goal 24-hour systolic blood pressure of \< 145 mmHg) for a total of 36 months.


Options:
A: Arm Label: Intensive Control of SBP; Type: EXPERIMENTAL; Interventions: Drug: Intensive control of SBP | Arm Label: Standard Control of SBP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of SBP | Intervention Type: DRUG; Name: Intensive control of SBP; Assigned to Arm(s): Intensive Control of SBP | Intervention Type: DRUG; Name: Standard control of SBP; Assigned to Arm(s): Standard Control of SBP
B: Arm Label: Intensive Control of Systolic Blood Pressure (SBP); Type: EXPERIMENTAL; Interventions: Drug: Intensive Control of Systolic Blood Pressure (SBP) | Arm Label: Standard Control of Systolic Blood Pressure; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard control of Systolic Blood Pressure (SBP) | Intervention Type: DRUG; Name: Intensive Control of Systolic Blood Pressure (SBP); Assigned to Arm(s): Intensive Control of Systolic Blood Pressure (SBP) | Intervention Type: DRUG; Name: Standard control of Systolic Blood Pressure (SBP); Assigned to Arm(s): Standard Control of Systolic Blood Pressure
C: Arm Label: Intensive; Type: EXPERIMENTAL; Interventions: Other: Anti-hypertensive therapy to SBP 130 mm Hg | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Other: Anti-hypertensive therapy to SBP 145 mm Hg | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 130 mm Hg; Assigned to Arm(s): Intensive | Intervention Type: OTHER; Name: Anti-hypertensive therapy to SBP 145 mm Hg; Assigned to Arm(s): Standard
D: Arm Label: Blood pressure; Type: EXPERIMENTAL; Interventions: Drug: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone | Intervention Type: DRUG; Name: Losartan, Losartan and HCTZ, Amlodipine , Spironolactone; Assigned to Arm(s): Blood pressure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: School-Based Telemedicine Enhanced Asthma Management: A Randomized Control Trial Using Novel Technology to Improve Preventive Asthma Care
Brief Summary: This project aims to improve guideline-based asthma care using enhanced communication and screening tools, telemedicine and directly observed therapy of preventive medications in city schools. Web-based screening will be used to identify children with persistent or poorly controlled asthma and to send reports to the child's primary care doctor. Children in the SB-TEAM group will receive a telemedicine asthma assessment in school and be prescribed a daily preventive asthma medication to be taken through school-based directly observed therapy. The overall aim of this study is to evaluate the use of the SB-TEAM intervention for improving guideline based care, enhancing adherence to effective preventive medications and at reducing morbidity among young urban children with asthma.


Options:
A: Arm Label: Tailored asthma management program; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored asthma management program | Arm Label: Generic web-based education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic web-based education | Intervention Type: BEHAVIORAL; Name: Tailored asthma management program; Assigned to Arm(s): Tailored asthma management program | Intervention Type: BEHAVIORAL; Name: Generic web-based education; Assigned to Arm(s): Generic web-based education
B: Arm Label: School-based Telemedicine Enhanced Asthma Mangement Group; Type: EXPERIMENTAL; Interventions: Other: School-Based Telemedicine Enhanced Asthma Management | Arm Label: Enhanced Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: School-Based Telemedicine Enhanced Asthma Management; Assigned to Arm(s): School-based Telemedicine Enhanced Asthma Mangement Group | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care Group
C: Arm Label: Paper Asthma Action Plan; Type: EXPERIMENTAL; Interventions: Other: Paper Asthma Action Plan | Arm Label: Mobile Phone; Type: EXPERIMENTAL; Interventions: Device: Mobile Phone | Intervention Type: OTHER; Name: Paper Asthma Action Plan; Assigned to Arm(s): Paper Asthma Action Plan | Intervention Type: DEVICE; Name: Mobile Phone; Assigned to Arm(s): Mobile Phone
D: Arm Label: CHESS + Case Mgt; Type: EXPERIMENTAL; Interventions: Behavioral: CHESS Internet telehealth | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHESS Internet telehealth; Assigned to Arm(s): CHESS + Case Mgt

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Non-Randomized, Study to Evaluate the Pharmacokinetics of Tranexamic Acid in Patients Undergoing Major Liver Resection
Brief Summary: Tranexamic acid (TXA) is an antifibrinolytic agent that has been shown to reduce blood loss and blood transfusion requirements in the following patient populations: multisystem trauma, liver transplantation, cardiac surgery and spine surgery. Patients undergoing major liver resection are at risk of severe perioperative blood loss and may also benefit from perioperative TXA administration.

This open label, non-randomized study to evaluate the pharmacokinetic and pharmacodynamic properties of two well studied dosing regimens of TXA will provide guidance in determining the optimal TXA dosing regimen for patients undergoing major liver resection. Compelling evidence of the effectiveness of TXA comes from the large multicentred, multi-national CRASH-2 trial where TXA was administered as a 1 g bolus + 1 g infusion over 8 hours. In liver transplant surgery, the following dose regimen has been shown to have great effect:10 mg/kg/h from the start of surgery until 2 hours after reperfusion of the liver transplant.

Although TXA is not currently approved for use in patients undergoing major liver resection, Health Canada has allowed the use of tranexamic acid for use in this research study.


Options:
A: Arm Label: Fibrin Pad; Type: EXPERIMENTAL; Interventions: Biological: Fibrin Pad | Arm Label: Standard of Care; Type: OTHER; Interventions: Procedure: Standard of Care | Intervention Type: BIOLOGICAL; Name: Fibrin Pad; Assigned to Arm(s): Fibrin Pad | Intervention Type: PROCEDURE; Name: Standard of Care; Assigned to Arm(s): Standard of Care
B: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Drug: No tranexamic acid | Arm Label: Dose 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Dose 2; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Intervention Type: DRUG; Name: No tranexamic acid; Assigned to Arm(s): Standard Care | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Dose 1, Dose 2
C: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
D: Arm Label: EVARREST® Fibrin Sealant Patch; Type: EXPERIMENTAL; Interventions: Biological: EVARREST® Fibrin Sealant Patch | Arm Label: Standard of Care (SoC); Type: OTHER; Interventions: Other: Standard of Care (SoC) | Intervention Type: BIOLOGICAL; Name: EVARREST® Fibrin Sealant Patch; Assigned to Arm(s): EVARREST® Fibrin Sealant Patch | Intervention Type: OTHER; Name: Standard of Care (SoC); Assigned to Arm(s): Standard of Care (SoC)

Answer: B